Linnaeus Therapeutics is a development-stage biotech company dedicated to transforming cancer treatment. They specialize in the identification and development of small molecule agents for cancer therapy. With a foundation of clinical experience, Linnaeus is focused on creating innovative therapies that address unmet needs in cancer care.

Founded in 2016, Linnaeus Therapeutics is a Penn Center for Innovation UPstart company, leveraging discoveries from the prestigious Ridky lab at the University of Pennsylvania. Their mission is to observe and learn from the clinical experience, allowing it to guide the identification of new therapeutic targets for cancer. With a diverse team of experts in management and drug development, Linnaeus Therapeutics combines complementary skill sets and domain expertise to expedite the translation of drug candidates into human trials.

They are driven by the goal of getting their groundbreaking therapies to patients as safely and efficiently as possible. Stay updated with the latest news and advancements from Linnaeus Therapeutics, as they continue to push the boundaries of cancer treatment. Contact Linnaeus to learn more about their transformative approach and how they listen to the clinical experience to develop revolutionary therapies